- 品番
- GC004
- 価格
- 196,000円(税抜) ※マルチカラーのFISH Probeもご用意可能です。お問い合わせください。
- 容量
- 200uL （22x22のカバーガラスを使用する場合、標本20枚のFISHができます）
- 遺伝子別名
- HGFR, AUTS9, RCCP2, MET, DFNB97
Related Articles
本製品を使用した研究論文 (13)
- Anaplastic lymphoma kinase (ALK)-rearranged lung cancer that showed exclusively scattered isolated cells devoid of mucin production in cytology Cureus 15(10), 2023
- Histological characteristics of lung adenocarcinoma with uncommon actionable alterations: special emphasis on METexon 14 skipping alterations Histopathology : 9 November 2020 (First published)
- Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer JCO Precision Oncology., Published online: March 24, 2020
- Liquid biopsy-based comprehensive gene mutation profiling for gynecological cancer using CAncer Personalized Profiling by deep Sequencing Sci Rep . 2019 Jul 18;9(1):10426. doi: 10.1038/s41598-019-47030-w.
- Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial Transl Oncol . 2019 Apr;12(4):597-601. doi: 10.1016/j.tranon.2018.12.009. Epub 2019 Jan 26.
- Changes in HER2 Expression and Amplification Status Following Preoperative Chemotherapy f or Gastric Cancer in vivo November-December 2018 : vol.32, No.6, p1491-1498
- Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604) European Journal of Cancer : Volume 105, December 2018, Pages 41-49
- Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR Oncotarget. 2017 Apr 4; 8(14): 23020–23032.
- MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation. BMC Cancer. 2015 Feb 6;15:31. doi: 10.1186/s12885-015-1019-1.
- Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study. Oncotarget. 2014 Apr 30;5(8):2293-304.
- Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients. Onco Targets Ther. 2014 Apr 3;7:513-24. doi: 10.2147/OTT.S60122. eCollection 2014.
- MET amplification as a potential therapeutic target in gastric cancer. Oncotarget. 2013 Jan;4(1):9-17.
- Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients. Lung Cancer. 2012 Jan;75(1):89-94. doi: 10.1016/j.lungcan.2011.06.004. Epub 2011 Jul 5.
